---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-006960"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T20:45:53.943844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptose reports Q3 net loss $9.8M; tuspetinib completes dose escalation with CRs in FLT3+ AML

## Summary
- Net loss $9.8M ($0.11/share) vs $11.3M ($0.13) in Q3 2021; cash $55.4M funds operations into Q1 2024.
- Tuspetinib (HM43239) completes Phase 1/2 dose escalation; 120mg selected for single-agent expansion, 80mg with venetoclax.
- FLT3-mutant patients with prior FLT3 inhibitor failure achieved complete remissions; responses also in FLT3 wildtype with TP53/NRAS.
- Luxeptinib G3 formulation shows ~18-fold bioavailability improvement; continuous dosing of 50mg Q12h to start shortly.
- USAN Council adopted generic name 'tuspetinib'; Aptose will use for all future references.

## SEC filing metadata
- accession: 0001171843-22-006960
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/f8k_110122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-006960
- JSON: https://secwatch.observer/filing/0001171843-22-006960.json
- Plain text: https://secwatch.observer/filing/0001171843-22-006960.txt

## Key facts
- Earnings Releases
  Aptose Biosciences Inc. reported the quarter ended September 30, 2022 results: revenue $ -, net income $9.8 million, EPS ($0.11 per share).
  - Period: the quarter ended September 30, 2022
  - Revenue: $ -
  - Net income: $9.8 million
  - EPS: ($0.11 per share)
  - Result: reported results
  source text: The net loss for the quarter ended September 30, 2022 was $9.8 million ($0.11 per share) compared with $11.3 million ($0.13 per share) for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm
- Earnings Releases
  Aptose Biosciences Inc. reported the nine months ended September 30, 2022 results: revenue $ -, net income $31.8 million, EPS $ (0.34).
  - Period: the nine months ended September 30, 2022
  - Revenue: $ -
  - Net income: $31.8 million
  - EPS: $ (0.34)
  - Result: reported results
  source text: Net loss for the nine-month period ended September 30, 2022 decreased by $9.2 million to $31.8 million, as compared to $41.0 million for the comparable period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184322006960/0001171843-22-006960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.